The effect of disease modifying therapies on CD62L expression in multiple sclerosis

BACKGROUND: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Voortman, Margarete Maria, Greiner, Paul, Moser, Daniel, Stradner, Martin Helmut, Graninger, Winfried, Moser, Adrian, Haditsch, Bernd, Enzinger, Christian, Fuchs, Siegrid, Fazekas, Franz, Fessler, Johannes, Khalil, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149021/
https://www.ncbi.nlm.nih.gov/pubmed/30263146
http://dx.doi.org/10.1177/2055217318800810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149021/
https://www.ncbi.nlm.nih.gov/pubmed/30263146
http://dx.doi.org/10.1177/2055217318800810

Ejemplares similares